Showing 1601-1610 of 5853 results for "".
Comorbidities in Immune-mediated Skin Disorders: What’s Coming
https://practicaldermatology.com/issues/january-february-2025/comorbidities-in-immune-mediated-skin-disorders-whats-coming/32968/Comorbidities in immune-mediated skin disorders (IMSDs) occur frequently and have a significant impact on disease severity, treatment, prognosis, and quality of life.SCALE 2024: Listen as Dr. Joel Cohen Interviews Dr. John H. Joseph on Clinical Trials for Injectables
https://practicaldermatology.com/error/404/John H. Joseph, MD, joins Joel Cohen, MD, to discuss his work on clinical trials for neuromodulators and filler products at Music City SCALE.Phio Pharmaceuticals Takes Aim at Skin Cancer
https://practicaldermatology.com/series/c-suite-chats/phio-pharmaceuticals-takes-aim-skin-cancer/24316/In the first episode of Practical Dermatology's C-Suite Chats, Robert Bitterman, CEO of Phio Pharmaceuticals, discusses the company's patented INTASYL technology. Learn more about this platform for creating and delivering uniquely modified siRNA compounds to treat cancer.Achieve Skin Tightening in 1-2-3
https://practicaldermatology.com/conferences/maui-derm-2024/achieve-skin-tightening-in-1-2-3/20239/Mitchel P. Goldman, MD, Founder and Medical Director, Cosmetic Laser Dermatology, and Medical Director, Platinum Dermatology Partners, explains the three basic technologies he swears by to tighten skin.DermWireTV: Atopic Dermatitis Guidelines, Derm Devices, and New Research
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-atopic-dermatitis-guidelines-derm-devices-and-new-research/20234/In this episode of DermWire TV, we report on the new atopic dermatitis guidelines, the long-term safety of upadacitinib, and novel energy-based dermatology devices. From the new at-home treatment for molluscum contagiosum to the discovery of genetic factors in early-onset Merkel cell carcinoma, thisGuselkumab in PsA: Exploring Patient-Reported Outcomes in Real-World Settings
https://practicaldermatology.com/topics/psoriasis/guselkumab-in-psa-exploring-patient-reported-outcomes-in-real-world-settings/20226/Philip Mease, MD, shares new real-world data showing that psoriatic arthritis patients who take Tremfya (guselkumab) report meaningful improvements in pain, physical function, and fatigue through six months.Recognizing Dermatologic Emergencies in Kids
https://practicaldermatology.com/conferences/scale-2023/recognizing-dermatologic-emergencies-in-kids/20198/Infections including congenital infections, syphilis, or HSV are the No. 1 cause of pediatric skin emergencies. Infantile hemangiomas in the airway can affect breathing and also require fast and early treatment, explains Thy Huynh, MD.Clinical Conversations: The Data for JAK Inhibitors in AD
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-the-data-for-jak-inhibitors-in-ad/20105/JAK inhibitors represent a new therapeutic class for the treatment of atopic dermatitis. Find out what the data show about their efficacy and tolerability in a conversation between Brad Glick, DO and Raj Chovatiya, MD. Discover how these drugs can fit into the treatment plan and how these experts diEducational Excellence
https://practicaldermatology.com/series/dermatology-education-foundation/educational-excellence/19994/The excellent faculty and top-notch education are the highlights of Dermatology Education Foundation conferences, says Kara S. Gooding, MMS, PA-C.Stay Relevant with Education
https://practicaldermatology.com/series/dermatology-education-foundation/stay-relevant-with-education/19989/Feed yourself new information and stay on top of data regarding new and existing medications in order to offer patients the best care possible, says Wendy Cantrell, CRNP, DNP. This is particularly important as new understanding of conditions like psoriasis and atopic dermatitis evolve and new treatm